Observes zanubrutinib use in adults with Waldenström's macroglobulinemia and other lymphomas
Tracks real-world zanubrutinib care and quality of life in adults with these blood cancers.
Plain-language title generated from the registry record
Registry title: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Key facts
- Where
- Lübeck, GermanySee the site
Where in Germany
- Lübecker Onkologische SchwerpunktpraxisLübeck, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT05326308
- Record updated
- 9 September 2026
- Original description
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.Read full original descriptionShow less
Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
Inclusion: Waldenström's macroglobulinemia (all treatment lines) OR; Chronic lymphocytic leukemia (all treatment lines) OR; Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy); Follicular lymphoma (≥3 treatment line); Signed and dated informed consent form; Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL; Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC; Treatment decision before inclusion into this non-interventional study; Age ≥18 years.
Exclusion: Contraindications according to SmPC for patients with WM, CLL, MZL or FL; Participation in an interventional clinical trial during zanubrutinib treatment.